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A NEUTROPHIL-DEPENDENT PATHWAY FOR THE GENERATION 
OF A NEUTRAL PEPTIDE MEDIATOR 
PARTIAL CHARACTERIZATION OF COMPONENTS AND 
CONTROL BY O~-I-ANTITRYPSIN* 
BY BRUCE U. WINTROUB,$ EDWARD J. GOETZL,§ AND K. FRANK AUSTEN 
(From the Harvard Medical School, Robert B. Brigham Hospital, 
Boston, Massachusetts 02120) 
(Received for publication 20 May 1974) 
Polymorphonuclear leukocytes have the capacity to supply proteolytic 
enzymes capable of generating kinin activity from a plasma protein substrate, 
kininogen, under diverse reaction conditions (1-3). Experiments, initially 
directed toward the mechanism of neutrophil-dependent kinin generation, 
have uncovered a different system which is controlled by ec-l-antitrypsin. 
Incubation of crude neutrophil homogenates with heated human plasma gen- 
erated a biologically active neutral peptide, distinct from bradykinin, derived 
from a plasma protein substrate chromatographically separable f om kininogen. 
The neutrophil enzyme responsible for the formation of neutral peptide was a 
serine-dependent protease sensitive to inhibition by plant-derived trypsin 
inhibitors and a-l-antitrypsin. 
Materials and Methods 
Bradykinin triacetate (Sandoz Pharmaceutical, Ltd., Basel, Switzerland); hexadimethrine 
bromide (Polybrene) and diisopropyl fluorophosphate (DFP) ~ (Aldrich Chemical o., In ., 
Milwaukee, Wisc.); disodium ethylenediamine tetraacetate (EDTA) nd tris hydroxymethyl 
aminoethane (Tris) (Fisher Scientific Co., Fair Lawn, N. J.); lima bean trypsin inhibitor 
(LBTI), soybean trypsin inhibitor (SBTI), pancreatic trypsin inhibitor (PI), ovomucoid 
trypsin inhibitor (OMTI), trypsin a d chymotrypsin (Worthington Biochemical Corp., Free- 
hold, N. J.); Hanks' balanced salt solution (Microbiological Associates, Inc., Bethesda, Md.); 
Ficoll, Blue dextran 2000, aldolase, ovalbumin, quater ary aminoethyl (QAE) Sephadex A-25, 
Sephadex G-15, Sephadex G-150, Sepharose 4B (Pharmacia Fine Chemicals, Inc., Piscataway, 
N. J.); human serum albumin (Schwartz/Mann Div., Becton, Dickinson & Co., Ora geburg, 
N. Y.); vitamin BI2 (Eli Lilly and Co., Indianapolis, Ind.); sodium diatrizoate (Hypaque) 
(Winthrop Laboratories, N. Y.); and goat antihuman alpha1 trypsin inhibitor (Miles Labora- 
tory, Kankakee, Ill.) were obtained as noted, o~-l-antitrypsin and o -2-macroglobulin (4) and 
* Supported by grants AI-07722 and AI-I0356 from The National Institutes ofHealth. 
:~ Postdoctoral Research Fellow of The Medical Foundation, I c. 
§ Investigator, Howard Hughes Medical Institute. 
1 Abbreviations u ed in this paper: DFP, diisopropyl fluorophosphate; LBTI, lima bean 
trypsin inhibitor; ng BK Eq, nanogram bradykinin equivalent; OMTI, ovomucoid trypsin 
inhibitor; PI, pancreatic trypsin inhibitor; QAE, quaternary aminoethyl; SBTI, soybean 
trypsin inhibitor; SRS-A, slow-reacting substance of anaphylaxis. 
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slow reacting substance of anaphylaxis (SRS-A) (5) were purified as previously described. The 
(null) a-l-antitrypsin-deficient plasma was obtained by Dr. Charles Reed (Univ. of Wiscon- 
sin) from the proband (6). 
Column chromatography was carried out at 4°C. Sephadex G-15 and Sepharose 4B filtration 
were performed with a 1.5 cm X 90-cm glass column with a flow rate of 10.0 ml/h and a collec- 
tion vol of 1.71 ml/tube. QAE Sephadex A-25 chromatography employed a 4.8 cm >( 55-cm 
glass column with a flow rate of 50 ml/h and a collection vol of 12 ml/tube. Sephadex G-150 
filtration was carried out in a 2.5 cm X 160-cm glass column pumped against gravity at a flow 
rate of 10 ml/h and a collection vol of 3 ml/tube. Protein was quantitated in column fractions 
by OD at 280 nm utilizing a Beckman DU-2 Spectrophotometer (Beckman Instruments, Inc., 
Fullerton, Calif.) or by Folin-Ciocalteu reaction. Chromatographic fractions were concen- 
trated with positive pressure chambers and UM-10 membranes (Amicon Corp., Lexington, 
Mass.). Unless otherwise indicated centrifugation steps were carried out at 4°C in an Inter- 
national PR-2 or PR-6 centrifuge (International Equipment Co., Needham Heights, Mass.). 
Smooth muscle contractile activity was routinely measured on an isolated, atropinized, 
mepyraminized guinea pig ileum obtained from 200-g Hartley guinea pigs; the ileum was 
suspended in Tyrode's solution and the contractile response standardized with synthetic 
bradykinin (7) and expressed as nanogram bradykinin equivalent (ng BK Eq). Kininlike 
activity was assessed on the estrous rat uterus suspended in DeJalon's olution (7). Reaction 
mixtures were directly bioassayed unless the procedure specifies concentration by lyophiliza- 
tion or flask evaporation. 
Preparation of Crude Neutrophil Extract.--Human neutrophils and mononuclear leukocytes 
were isolated and purified from whole human blood by dextran sedimentation f red blood cells 
and fractionation of white blood cells by centrifugation on Ficoll-Hypaque cushions (8). Puri- 
fied neutrophils were suspended in Hanks' solution (10 s neutrophils/ml) and broken by re- 
peated freezing with dry ice in acetone and thawing at room temperature. Broken cells were 
further fragmented for 3 min at 4°C by means of exposure to a probe sonicator (Ultrasonics 
Instruments International, Inc., Farmingdale, N. Y.). The cell debris was removed by cen- 
trifugation at 400 g for 20 min, and the supernate was retained as crude neutrophil extract. 
Preparation of Heat-Inactivated Plasma.--Whole human blood, collected in EDTA (1.0 
mg/ml) and hexadimethrine bromide (36.5/zg/ml), was centrifuged at 900 g for 20 rain and the 
supernatant plasma harvested. Plasma was then heated for 2 h at 61°C to inactivate inhibitors, 
proteolytic enzymes, and plasma kallikrein, and centrifuged at 900 g for 5 rain to remove 
precipitated materials. The resulting supernate was employed as heat-inactivated plasma. A 
variety of normal human donors were utilized interchangeably as sources for crude neutrophil 
extract and heat-inactivated plasma. 
RESULTS 
The time-course of generation of the ileal contract ing principle was studied 
at 37°C in replicate reaction mixtures containing 100 #1 of crude neutrophi l  
extract  derived from 10; neutrophi ls and 900 ~1 of heat- inact ivated plasma. 
The reaction was stopped at vary ing t ime intervals by addit ion of 4.0 ml ice- 
cold absolute ethanol. After  centr i fugation for 10 min at 4°C, the supernate, 
which contained at least 90 % of the contracti le act iv i ty  generated, was flask 
evaporated to dryness and resuspended in distil led water for bioassay. As 
depicted in Fig. 1, the generation of contracti le act iv i ty proceeded rapidly, 
with the appearance by 10 rain of 50% of the maximal act iv i ty demonstrable 
at 2 h. The pH of the standard reaction mixture of undiluted, heat- inact ivated 
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FIG. 1. Time-course of generation f contractile activity from crude neutrophil extract 
and heat-inactivated plasma. 1,624 ng BK Eq/ml of contractile activity were present at 120 
min and represent 100% of available activity. 
plasma and crude neutrophil extract was 7.8-8.0, representing the upper range 
of a broad pH optimum of pH 5.0-8.2. 
Neutral Peptide.-- 
Physical characteristics: In order to achieve partial purification and to deter- 
mine the approximate size of the contractile principle, 10,000 ng BK Eq were 
generated from 4.5 ml of heat-inactivated plasma by incubation with 500 #1 
of neutrophil extract from 5 X 107 neutrophils for 60 min at 37°C. The activity 
recovered from the supernatant after 80% ethanol precipitation was flask 
evaporated, resuspended in 1.0 ml of 0.01 M acetic acid and filtered through a 
previously calibrated Sephadex G-15 column equilibrated in 0.01 M acetic acid. 
Individual fractions were bioassayed, and a single peak of contractile activity 
containing 90 % of that applied was found (Fig. 2) corresponding to the brady- 
kinin marker at 65 % bed vol and consistent with a tool wt of approximately 
1,000. 
In order to define the charge of the contractile principle, 1,000 ng BK Eq of 
Sephadex G-15 purified material were subjected to isoelectric focusing in 4 % 
acrylamide gels using pH 3.0-10.0 and subsequently pH 5.0-8.0 ampholytes 
(9). The gels were sliced into 5-mm long cross-sections, washed, eluted in 500 
~l distilled water for 12 h at 4°C, and bioassayed after determining the pH. 
Activity was found only in fractions which corresponded to pH 7.0-8.0 with 
pH 3.0-10.0 ampholytes and to pH 7.3-7.5 with pH 5.0-8.0 ampholytes; 
recovery was 35-40 % of the activity applied. 
The neutral isoelectric point of the contractile activity clearly distinguished 
it from the cationic peptide, bradykinin. In order to explore further the func- 
tional homogeneity of the Sephadex G-15 purified principle, 100 #1 of 0.01 M 
acetic acid containing 1,000 ng BK Eq of activity were subjected to descending 
paper chromatography in butanol:acetic a id:water (4:1:5) for 12 h at room 
temperature with DNP-lysine as a reference marker (10). The paper strip was 
cut transversely into 2-cm pieces and each was eluted with 3.0 ml 0.01 M 
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Sephadex G-15 chromatography of contractile activity. FIG. 2. 
acetic acid. Eluate fractions were lyophilized, resuspended in 1 ml Tyrode's 
solution, and bioassayed. Activity was found in a single peak, representing 10 % 
of the starting activity, which migrated 4-8 cm from the origin, and had an 
Rf of 0.25 with respect o DNP-lysine. 
Susceptibility to inactivation by chymotrypsin and trypsin: In order to deter- 
mine if the active principle was a peptide, its susceptibility to chymotrypsin 
and trypsin inactivation was compared to that of bradykinin. 200 ng BK Eq 
of Sephadex G-15 purified contractile principle or 400 ng of bradykinin in 100 
~| of Tris:acetate pH 7.8 buffer were incubated with 1.0 mg chymotrypsin or 
1.0 mg trypsin in 900 #1 of the same buffer for 30 rain at 37°C. The reaction 
mixtures and control solutions of contractile principle and bradykinin were 
boiled for 15 rain. Direct bioassay of the mixtures revealed that both enzymes 
completely inactivated the neutral contractile principle while bradykinin was 
susceptible only to chymotrypsin. Taken together with the physical chemical 
data, these studies permit designation of the active principle as .neutral pep- 
tide. 
Biologic activity: The contraction of the atropinized and antihistamine- 
treated guinea pig ileum elicited by crude or partially purified neutral peptide 
was slow and more reminiscent of the action of SRS-A than of histamine or 
bradykinin. Repeated maximal contractions were not associated with tachy- 
phylaxis. A concentration of neutral peptide qual to 13 ng BK Eq as assayed 
on the guinea pig ileum recorded less than a 0.4 ng BK Eq on the estrous rat 
uterus. Thus, neutral peptide did not have the contractile characteristics of a 
kinin peptide. 
Neutrophil Protease.-- 
Inhibition: A 100-#l portion of crude neutrophil extract front 107 cells was 
subjected to heating at 60°C for 15 rain before incubation with 900/~1 of heat- 
inactivated plasma for 5 rain at 37°C. Unheated, crude neutrophil extract 
generated 500 ng BK Eq of neutral peptide, while the heated extract had no 
activity. 
In order to characterize further the heat-labile neutrophil extract protease, 
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100-/zl portions of neutrophil extract from 107 neutrophils were exposed to 
varying doses of DFP in 10/zl of 0.0035 M PO4-buffered 0.15 M NaC1 (pH 
7.4) for 60 min at 37°C followed by extensive dialysis in the same buffer to 
remove residual DFP. 50/zl of each reaction mixture were then mixed with 450 
#1 of heat-inactivated plasma, incubated for 5 rain at 37°C, placed on ice, and 
the samples directly bioassayed for neutral peptide. Complete inhibition of the 
neutral peptide-generating activity occurred with 5 X 10 -4 M DFP consistent 
with a serine at the active site of the heat labile protease in crude neutrophil 
extract. 
The DFP-sensitive neutrophil protease was further characterized by inter- 
acting 50 pl of crude extract from 5 X 106 neutrophils with 50 #l of equimolar 
quantities of lima bean, soybean, pancreatic, and ovomucoid trypsin inhibitors 
for 15 min at 37°C before addition of 450 pl of heat-inactivated plasma. 5 min 
later, the reaction mixtures were placed on ice and the neutral peptide gener- 
ated was directly bioassayed. At a concentration of 5 X 10- 7 M, inhibition 
achieved with lima bean trypsin inhibitor was 85%; with soybean trypsin 
inhibitor, 35 %; with pancreatic trypsin inhibitor, 10%; and with ovomucoid 
trypsin inhibitor, 0 % (Fig. 3). 
The susceptibility of the neutrophil serine protease to inhibition by 5 X 
10 -7 M lima bean and soybean trypsin inhibitors prompted an analysis of the 
effect of the major human plasma trypsin inhibitor, a-l-antitrypsin. 50-/zl 
portions of extracts from 5 X 106 neutrophils were preincubated for 15 min at 
37°C with 1.1-110 #g of highly purified a-l-antitrypsin or 80 #g of a-2-macro- 
globulin in 100 pl 0.0035 M POd-buffered 0.15 M NaCl (pH 7.4). These mix- 
tures were then incubated with 450/~1 heat-inactivated plasma for 5 min at 
37°C and placed on ice before bioassay. Fig. 4 demonstrates a linear relation- 
ship between the percent inhibition of neutral peptide generation and the log 
of the a-l-antitrypsin dose. The dose of a-l-antitrypsin capable of inhibiting 
the neutrophil protease from 5 X 106 cells by 50% was 11 pg, which is less 
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FiG. 3. LBTI, SBTI, PI, and OMTI inhibition of neutral peptide-generating activity in 
crude neutrophil extract. The untreated extract generated 330 ng BK Eq/ml neutral peptide. 
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Fxo. 4. a-l-antitrypsin hibition of neutral peptide-generating activity in crude neutro- 
phil extract. The untreated xtract produced 462 ng BK Eq/ml neutral peptide. 
than 1.0% of the normal plasma a-l-antitrypsin level .(11). a-2-macroglobulin 
had no detectable ffect. The functional integrity of a-2-macroglobulin was 
established by total inhibition of the capacity of kallikrein to generate 500 ng 
of bradykinin from 1.0 ml of heat-inactivated plasma (4). 
The significance of plasma inhibitors other than a-l-antitrypsin was assessed 
by interacting crude neutrophil extract with the plasma of a patient homo- 
zygous for a-l-antitrypsin deficiency (ZZ) with 25% of the normal evel (11) 
and with the plasma of the patient with no detectable (null) a-l-antitrypsin 
(6). 50/~1 of neutrophil extract were incubated for 30 rain at 37°C with 450/A 
of whole unheated a-l-antitrypsin-deficient plasma (null), a-l-antitrypsin 
deficient plasma (ZZ) or whole unheated normal or heat-inactivated plasma. 
The reaction mixtures were placed on ice and bioassayed. 500 ng BK Eq of 
activity were generated from (null) a-l-antitrypsin deficient plasma or heat- 
inactivated normal plasma while no activity appeared in a-l-antitrypsin defi- 
cient (ZZ) or unheated normal plasma. Thus, a-l-antitrypsin appeared to be 
the only significant inhibitor of the neutrophil protease. 
Subcellular localization: 1.6 X l0 s purified neutrophils and 1.2 X l0 s 
mononuclear leukocytes were homogenized in 20% sucrose. 25% by vol of 
each cell type was assayed as broken cells to determine total available sub- 
cellular enzyme markers, neutral peptide-generating activity and neutral 
peptide-destroying activity. 75% of each broken cell type was subjected to 
stepwise, differential centrifugation at 100 g, 400 g, and 17,000 g. Precipitates 
were washed, resuspended in 0.5 ml Hanks' solution, and sonicated for 3 rain 
at 4°C. 100-/A portions of each fraction were assayed for neutral peptide-gen- 
erating or destroying activity and 50-/A portions were assayed for each of the 
subcellular enzyme markers, lactic dehydrogenase (12), alkaline phosphatase 
(13), and/~-glucuronidase (14). 200-#1 portions of each fraction were dialyzed 
for 72 h at 4°C against 0.01 M Tris-buffered 0.15 M NaC1 (pH 7.4) before 
assaying for 5'-nucleotidase (15). Neutral peptide destruction was assessed by 
addition of 100 ng BK Eq of Sephadex G-15 purified neutral peptide to 100 ~1 
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of each subcellular fraction, incubation for 30 min at 37°C, and immediate 
bioassay of iced mixtures. 90% of the starting neutral peptide-generating 
activity was associated with 55 % of the membrane marker 5'-nucleotidase 
(16) in the 100 g precipitate fraction while less than 5 % of the activity was 
present in each of the 400 g or 17,000 g precipitate fractions and none in the 
17,000 g supernate (Fig. 5)./~-glucuronidase and alkaline phosphatase, which 
are lysosomal markers (17), were most prominent in the 17,000 g precipitate 
while lactic dehydrogenase, a cytoplasmic marker (17), was principally localized 
in the 17,000 g supernate. The 400 g fraction contained only isolated nuclei by 
phase microscopic examination. Ability to destroy neutral peptide was absent 
in the broken cell preparation but was associated with the 100 g subcellular 
FIG. 5. Stepwise, differential centrifugation of purified, disrupted human neutrophils and 
assay for neutral peptide-generating activity and subcellular fraction marke s. Th teotal 
activity was 586 mg NADH utilized/h at pH 7.5, 25°C of lactic dehydrogenase, 357~zM p-NO2 
phenol generation at pH 10.5, 37°C of alkaline phosphatase, 163 /zg phenolphthalein gen- 
erated/h at pH 6.8, 37°C of/~-glucuronidase, 246/~g phosphate generated/h  pH 7.5, 37°C 
of 5t-nucleotidase, and 5,010 ng BK Eq neutral peptide/1.2 )< 106 neutrophils of neutrophil 
protease. 
fraction. Mononuclear cells manifested no neutral peptide-generating or de- 
stroying activity. 
The finding that the neutral peptide-generating activity was present only 
with the 100 g fraction suggested an association with the membrane or some 
other rapidly sedimenting debris. Accordingly, 1.0 ml of the crude neutrophil 
extract routinely used as a source of neutral peptide g nerating activity was 
subjected to gel filtration through Sepharose 4B equilibrated in 0.0035 M PO4 
buffered 0.15 M NaCI (pH 7.4). 200 #1 of each column fraction was incubated 
with 200 #1 of heat-inactivated plasma for 10 min at 37°C before placing the 
samples on ice and direct bioassay of neutral peptide generated. The capacity 
to generate neutral peptide was present only in excluded fractions, in associa- 
tion with 64% of the 5'-nucleotidase activity, and with a recovery of 90% of 
starting neutral peptide-generating activity. 
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Since the neutral peptide-generating activity was associated with a large, 
rapidly sedimenting structure, an attempt was made to inhibit the activity in 
intact and fragmented cells with an inhibitor which might not rapidly penetrate 
the neutrophil. Intact neutrophils were exposed to c~-l-antitrypsin, 260 #g/l@ 
cells in 1.0 ml of Hanks' solution, for 60 rain at 37°C before repeated washing 
and resuspension i  1.0 ml Hanks' solution. 50% of the a-l-antitrypsin treated 
and untreated control cells were then fragmented by freeze-thawing and soni- 
cation. 100 #1 of either intact cells or extract were incubated with 900 ~1 of 
heat-inactivated plasma for 5 rain at 37°C, before addition of 4.0 ml cold etha- 
nol, flask evaporation of the supernate, resuspension i 1.0 ml distilled water 
and bioassay. The neutral peptide-generating ability of intact cells fell 54% 
from 125 to 58 ng BK Eq/ml and that of the subsequently fragmented cells 
46%, from 838 to 450 ng BK Eq/ml after pretreatment of intact cells with 
a-l-antitrypsin. 
Plasma Substrate for the Neutrophil Protease.--lO0 ml fresh plasma which 
had been dialyzed for 8 h at 4°C against 5 liters 0.0075 M Tris:HC1, pH 8.0, 
with two changes of buffer and centrifuged for 20 rain at 4°C at each buffer 
change to remove precipitated protein, were applied to a QAE Sephadex A-25 
column equilibrated with 0.0075 M Tris: HC1, pH 8.0. The column was washed 
overnight with starting buffer and a 0.3 M linear sodium chloride gradient 
applied. 500-#1 portions of each fraction to be bioassayed for neutral peptide 
activity were heated for 2 h at 61°C before interaction with 50 #1 crude neutro- 
phil extract for 30 rain at 37°C. A single peak of plasma substrate for neutrophil 
protease was detected late in the albumin region at 12.0 mS following the 
kininogen peak at 10.9 mS (Fig. 6) with a 61% recovery of starting activity. 
a-l-antitrypsin, as detected by Ouchterlony immunodiffusion, chromatographed 
in the albumin region and overlapped the neutrophil protease plasma substrate 
peak. Fractions 120-140, containing neutrophil protease plasma substrate, 
180 
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FIG. 6. Plasma substrate for neutrophil protease and kininogen i  the albumin peak of 
plasma chromatographed on QAE Sephadex A-25. Kininogen was assa:yed functionally by 
trypsin cleavage and release of bradykinin (18). 
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were pooled and concentrated to 10.0 ml and a 3.0-ml portion was filtered 
through Sephadex G-150 equilibrated in 0.0035 M PO4-buffered 0.15 M NaC1 
(pH 7.4). Heated fractions were assayed for substrate as above, and a single 
peak which corresponded to a tool wt of 85-95,000 was detected preceding the 
main protein peak. Kininogen, as assayed functionally by trypsin cleavage and 
release of bradykinin (18), was not recognized in the filtration step. 
The isolation procedure for substrate was repeated in identical fashion using 
100 ml of plasma from the (null) a-l-antitrypsin-deficient patient. QAE Seph- 
adex A-25 chromatography demonstrated a single peak of plasma substrate 
for neutrophil protease which eluted after kininogen at 12.0 mS, and could be 
identified with or without heating. Heating, however, was associated with a 
twofold increase of neutral peptide generation throughout the entire substrate 
peak, indicating that heating either increased substrate susceptibility or de- 
stroyed an inactivator of the neutral peptide since a-l-antitrypsin was absent 
from the starting material. Sephadex G-150 gel filtration of the pooled, con- 
centrated substrate-containing fractions (Fig. 7) revealed an ascending region 
in which neutral peptide generation was not augmented by the heat-inactiva- 
tion effect and a descending region in which heating increased neutral peptide 
generation. The presence of a heat-labile neutral peptide inactivator in the 
descending region was established by incubating 100 ng BK Eq of Sephadex 
G-15 purified neutral peptide with 200 ul of unheated substrate-containing 
(e) 
(z~,O) • Protein Concentration 
l~ 200 1 0 Unheated Fractions 2.0 
Heated Fraction 
!~ t 20 t.2 
40 0.4 
,20 t7,o ,60 ~4%o- 200 
FRACTION NUMBER 
FIO. 7. Sephadex G-150 filtration of plasma substrate for neutrophil protease obtained by 
QAE Sephadex chromatography of plasma from the (null) a-l-antitrypsin-deficient patient. 
Values for protein concentration are net absorption at 600 nM. The column was previously 
calibrated with aldolase, human serum albumin, and chymotrypsinogen which peaked in frac- 
tion 132, 171, and 193 respectively. 
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fraction for 30 rain at 37°C. Complete inactivation of neutral peptide occurred 
in those fractions of substrate whose capacity to generate neutral peptide was 
augmented by heating, while there was no inactivation i  the substrate frac- 
tions unaffected by heating. 
DISCUSSION 
A biologically active, low molecular weight neutral peptide mediator cleaved 
from a plasma protein substrate by a serine protease associated with the neu- 
trophil membrane has been recognized. The formation of neutral peptide is 
exquisitely controlled by the action of a-l-antitrypsin on the neutrophil pro- 
tease, and the peptide mediator is inactivated by a plasma factor separable 
from the other reactants. The neutrophil protease responsible for neutral pep- 
tide generation is distinguished from a-l-antitrypsin inhibitable lysosomal 
esterases such as neutral eukocyte protease (19), elastase (20), and the kinin- 
forming enzyme (3) by its subcellular location (Fig. 5) and from plasma kalli- 
krein by the failure of a-2-macroglobulin to inhibit its action (4). The substrate 
is distinguished antigenically 2 and chromatographically from kininogen (Fig. 
6), and there are critical physical, chemical, and functional differences between 
neutral peptide and bradykinin. This does not preclude the possibility that 
any of the five recognized components may participate in other reaction path- 
ways of host defense and inflammation. 
The biologically active mediator generated by the interaction of the neutro- 
phil protease and the plasma substrate was designated neutral peptide because 
of its isoelectric point of 7.3-7.5 and inactivation by chymotrypsin and tryp- 
sin. Only a single functional species of neutral peptide was recognized by iso- 
electric focusing, descending paper chromatography, and Sephadex G-15 filtra- 
tion. Sephadex G-15 filtration revealed a tool wt for neutral peptide indistin- 
guishable from the marker nonapeptide bradykinin, approximately 1,000 (Fig. 
2). Neutral peptide elicits a slow contraction of the isolated guinea pig ileum 
pretreated with atropine and mepyramine, has little activity on the estrous rat 
uterus and increases vascular permeability in guinea pig skin. 
The neutrophil enzyme responsible for the generation of neutral peptide 
(Fig. 1) was not detectable in purified mononuclear cells, was labile to heating 
at 61°C for 15 min, and was a tryptic serine protease based on its inactivation 
by DFP (21) and inhibition by lima bean and soybean trypsin inhibitors (Fig. 
3). Several lines of evidence suggest that the protease is available on the mem- 
brane possibly as an ectoenzyme. The protease activity was present only in 
the excluded vol of gel filtration of the crude neutrophil extract hrough Sepha- 
rose 4B in association with the membrane marker 5'-nucleotidase, implying 
association w!th particles of a tool wt greater than 10 million. Subcellular f ac- 
tionation of purified human neutrophils ocated the neutral peptide-generating 
activity in the heaviest fraction containing predominantly fragments of cells 
2 Spragg, J. S. Unpublished observation. 
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with cytoplasmic membrane (Fig. 5) and failed to disclose activity with the 
fractions containing principally nuclei, lysosomes, or cytoplasm. Finally, 
¢z-l-antitrypsin treatment of intact neutrophils with an amount known to 
inhibit crude neutrophil extract by about 50% (Fig. 4) inhibited both intact 
cells and their broken cell product by that same percent. As o~-l-antitrypsin is 
a plasma protein, it would not be expected to enter cells rapidly by simple 
diffusion and it thus seems likely that its inhibition of the neutrophil serine 
protease of intact cells occurs at the membrane. 
The use of heat inactivation at 61°C for 2 h proved critical to the formation 
and stability of the neutral peptide in normal plasma and hence to the isola- 
tion of substrate from plasma. The heat-labile inhibitor of neutral peptide for- 
mation in plasma proved to be o~-l-antitrypsin, a-l-antitrypsin chromato- 
graphed with substrate on anion exchange chromatography and thus only 
substrate isolated from a (null) a-l-antitrypsin deficient patient yielded neutral 
peptide without a heat inactivation step before interaction with the neutrophil 
protease (Fig. 7). An inactivator chromatographed with the substrate on QAE 
Sephadex but was distinguished on Sephadex G-150 filtration by its appearance 
only on the descending limb of the substrate peak (Fig. 7). 
The exquisite sensitivity of the neutrophil serine protease to purified o~-l- 
antitrypsin (Fig. 4) was recognized by the capacity of 1% of the normal plasma 
concentration of a-l-antitrypsin to suppress the neutral peptide-generating 
activity derived from the neutrophils contained in the same vol of whole blood. 
Indeed, neutral peptide generation i  plasma occurred only with plasma of a 
unique patient with no detectable o~-l-antitrypsin. The recognition of a neutro- 
phil protease with a-l-antitrypsin as the only readily demonstrable control 
protein raises the possibility that neutrophil accumulation might overwhelm 
the limited levels in cz-l-antitrypsin-deficient persons, thereby permitting 
cleavage of substrate for neutral peptide as well as other undefined protease 
activity. 
SUMMARY 
A biologically active neutral peptide mediator is cleaved from a plasma 
protein substrate by an a-l-antitrypsin-inhibitable serine protease apparently 
residing on the membrane of the human neutrophil. The peptide mediator has 
an approximate mol wt of 1,000, and is distinguished from the kinin peptides 
by a neutral isoelectric point, susceptibility to inactivation by trypsin as 
well as chymotrypsin and activity on the isolated, atropinized, and anti- 
histamine-treated guinea pig ileum with relatively little action on the estrous 
rat uterus. The neutrophil protease is fully inhibitable by DFP, trypsin inhibi- 
tots from lima or soy bean, and a-l-antitrypsin and is associated with the high 
tool wt fragments of the neutrophil and not the nuclear, lysosomal, or cyto- 
plasmic subcellular f action. The substrate has an approximate ool wt of 90,000 
and is chromatographically separable from kininogen. The exquisite sensitivity 
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of the neutrophil protease to a-l-antitrypsin was established both by inhibition 
with highly purified ~-l-antitrypsin and by the inability of the protease to 
generate detectable neutral peptide in a homozygous (ZZ) a-l-antitrypsin- 
deficient patient without heat inactivation of the residual inhibitor. On the 
other hand, plasma from a (null) a-l-antitrypsin-deficient patient supported 
neutral peptide generation and revealed an additional factor which inactivated 
neutral peptide. 
We are grateful for the excellent technical assistance of Ms. Carol Sena and Ms. Janet 
Woods. 
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